asenapine
- Generic Name
- asenapine
- Brand Names
- Saphris, Secuado, Sycrest
- Drug Type
- Small Molecule
- Chemical Formula
- C17H16ClNO
- CAS Number
- 65576-45-6
- Unique Ingredient Identifier
- JKZ19V908O
- Background
Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as ...
- Indication
适用于成人精神分裂症和双相情感障碍患者的治疗。
- Associated Conditions
- Bipolar 1 Disorder, Mixed manic depressive episode, Schizophrenia, Acute Manic episode
- Associated Therapies
- Maintenance therapy
Treating Acutely Agitated Patients With Asenapine Sublingual Tablets
- First Posted Date
- 2011-07-22
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Unity Health Toronto
- Target Recruit Count
- 120
- Registration Number
- NCT01400113
- Locations
- 🇺🇸
St. Joseph's Hospital Health Center-Comprehensive Psychiatric Emergency Program (CPEP), Syracuse, New York, United States
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 165
- Registration Number
- NCT01395992
- Locations
- 🇺🇸
Forest Investigative Site 1000, Austin, Texas, United States
Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384)
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2015-12-04
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 561
- Registration Number
- NCT01396291
- Locations
- 🇧🇬
Forest Investigative Site 3106, Sofia, Sofia-Grad, Bulgaria
🇧🇬Forest Investigative Site 3103, Varna, Bulgaria
🇭🇷Forest Investigative Site 3154, Zagreb, Grad Zagreb, Croatia
Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disorder (P05898)
- First Posted Date
- 2011-05-09
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 322
- Registration Number
- NCT01349907
Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 157
- Registration Number
- NCT01244828
Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)
- Conditions
- Interventions
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 404
- Registration Number
- NCT01244815
Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)
- Conditions
- Interventions
- First Posted Date
- 2010-08-27
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 204
- Registration Number
- NCT01190267
Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 201
- Registration Number
- NCT01142596
Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691)
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 367
- Registration Number
- NCT00764478
Study of Asenapine in Elderly Subjects With Psychosis (A7501021)(P05717)
- First Posted Date
- 2006-01-24
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 122
- Registration Number
- NCT00281320
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.